Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system

Headache

Volumn 52, Issue 4, 2012, Pages 612-624

  Smith, Timothy R ^a   Goldstein, Jerome ^b   Singer, Richard ^c   Pugach, Neil ^d   Silberstein, Stephen ^e   Pierce, Mark W ^f  

^a St John's Mercy Health Care   (United States)

^b San Francisco Clinical Research Center   (United States)

^c Neurology Clinical Research Inc   (United States)

^d Thomas Jefferson University ^*

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f NuPathe Inc   (United States)

Author keywords

5HT1B 1D agonist; formulation; headache; migraine; sumatriptan; transdermal; triptan

Indexed keywords

NP 101; SUMATRIPTAN; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; APPLICATION SITE DISCOLORATION; APPLICATION SITE PAIN; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE VESICLE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DEHYDRATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; OPEN STUDY; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SKIN BRUISING; SKIN EXFOLIATION; SKIN REDNESS; STOMACH PARESIS; TRANSDERMAL PATCH; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IONTOPHORESIS; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; PRURITUS; SUMATRIPTAN; TIME FACTORS; TRANSDERMAL PATCH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859712960     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02094.x     Document Type: Article

References (33)

1. Rasmussen BK,. Epidemiology. In:, Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York, NY: Raven Press; 1993: 15-20.
2. Taylor FR, Kaniecki RG,. Symptomatic treatment of migraine: When to use NSAIDs, triptans, or opiates. Curr Treat Options Neurol. 2011; 13: 15-27.
3. Cady RK, Schreiber CP, Farmer KU,. Understanding migraine: Advancing from clinical trials to clinical practice. Headache Care. 2004; 1: 183-190.
4. Silberstein SD,. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics. 2010; 7: 153-158.
5. Bigal M, Rapoport A, Aurora S, et al,. Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden. Headache. 2007; 47: 475-479.
6. Johnston MM, Rapoport AM,. Triptans for the management of migraine. Drugs. 2010; 70: 1505-1518.
7. Lipton RB, Stewart WF,. Acute migraine therapy: Do doctors know what migraine patients want from therapy? Headache. 1999; 39 (Suppl. 2): S20-S26.
8. Rapoport AM, Freitag F, Pearlman SH,. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010; 24: 929-940.
9. Silberstein SD,. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995; 35: 387-396.
10. Lipton RB, Stewart WF, Diamond S, et al,. Prevalence and burden of migraine in the United States: Data from the American Migraine II Study. Headache. 2001; 41: 646-657.
11. National Headache Foundation. Migraine patient survey, April 2010. Available at: (accessed November 27, 2010).
12. Valade D,. Early treatment of acute migraine: New evidence of benefits. Cephalalgia. 2009; 29 (Suppl. 3): 15-21.
13. Aurora SK, Kori SH, Barrodale P, et al,. Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. Headache. 2006; 46: 57-63.
14. Volans GN,. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975; 2: 57-63.
15. Tokola RA, Neuvonen PJ,. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984; 17: 67-75.
16. Rapoport AM, Tepper SJ, Bigal ME, et al,. The triptan formulations: How to match patients and products. CNS Drugs. 2003; 17: 431-447.
17. Fuseau E, Petricoul O, Moore KHP, et al,. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet. 2002; 41: 801-811.
18. Uemura N, Onishi T, Mitaniyama A, et al,. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005; 25: 199-208.
19. Patel SR, Zhong H, Sharma A, et al,. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm. 2007; 66: 296-301.
20. Pierce M, Marbury T, O'Neill C, et al,. Zelrix: A novel transdermal formulation of sumatriptan. Headache. 2009; 49: 817-825.
21. Siegel SJ, O'Neill C, Dube LM, et al,. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007; 24: 1919-1926.
22. Goldstein J, Pugach N, Smith T, et al,. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Abstract. Headache. 2010; 50: 509-515.
23. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
24. Davies GM, Santanello N, Lipton R,. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000; 20: 554-560.
25. Bouchard J, Cortelli P, Dahlöf C, et al,. A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. Pharmacoeconomics. 1997; 11 (Suppl. 1): 43-50.
26. Solomon GD, Santanello N,. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000; 55 (Suppl. 2): S29-S35.
27. Dowson AJ, Charlesworth BR, Green J, et al,. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: Results of the INDEX trial. Headache. 2005; 45: 17-24.
28. Brandes JL, Smith T, Diamond M, et al,. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache. 2007; 47: 886-894.
29. Heywood J, Bomhof MA, Pradalier A, et al,. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia. 2000; 20: 470-474.
30. Cabarrocas X, Esbri R, Peris F, et al,. Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study. Headache. 2001; 41: 57-62.
31. Imitrex tablets prescribing information. Research Triangle Park, NC: GlaxoSmithKline, February 2010. Available at: (accessed August 24, 2011).
32. Imitrex nasal spray prescribing information. Research Triangle Park, NC: GlaxoSmithKline, February 2010. Available at: (accessed August 24, 2011).
33. Imitrex injection prescribing information. Research Triangle Park, NC: GlaxoSmithKline, February 2010. Available at: (accessed August 24, 2011).